Immunotherapy at large: Balancing tumor immunity and inflammatory pathology

Nat Med. 2013 Sep;19(9):1100-1. doi: 10.1038/nm.3335.
No abstract available

MeSH terms

  • Animals
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • CTLA-4 Antigen / antagonists & inhibitors*
  • CTLA-4 Antigen / immunology
  • Drug Therapy, Combination
  • Humans
  • Immunotherapy
  • Ipilimumab
  • Melanoma / drug therapy*
  • Melanoma / immunology
  • Mice
  • Nivolumab
  • Programmed Cell Death 1 Receptor / antagonists & inhibitors*
  • Programmed Cell Death 1 Receptor / immunology
  • T-Lymphocytes / immunology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • CTLA-4 Antigen
  • Ipilimumab
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor
  • Nivolumab
  • pembrolizumab